ASCO 2021

Can Immunotherapy Be a Cure in Advanced Bladder or Kidney Cancer?

ASCO 2021 Bladder Cancer

Can Immunotherapy Be a Cure in Advanced Bladder or Kidney Cancer?

By Meg Barbor, MPH

Adding Tukysa to the Treatment Regimen Extends Survival in Patients with HER2-Positive Metastatic Breast Cancer

ASCO 2021 Breast Cancer

Adding Tukysa to the Treatment Regimen Extends Survival in Patients with HER2-Positive Metastatic Breast Cancer

Tecentriq Slashes Risk of Cancer Progression, Death in Patients with Early-Stage Non–Small-Cell Lung Cancer and PD-L1 Expression

Lung Cancer ASCO 2021

Tecentriq Slashes Risk of Cancer Progression, Death in Patients with Early-Stage Non–Small-Cell Lung Cancer and PD-L1 Expression

By Phoebe Starr

ASCO 2021 Highlights

Bavencio Leads to Long-Term Survival in Patients with Metastatic Merkel-Cell Carcinoma

Skin Cancer ASCO 2021

Bavencio Leads to Long-Term Survival in Patients with Metastatic Merkel-Cell Carcinoma

ASCO 2021 Highlights

Libtayo Safe and Effective in Immunocompromised Patients with Advanced Skin Cancer

Skin Cancer ASCO 2021

Libtayo Safe and Effective in Immunocompromised Patients with Advanced Skin Cancer

ASCO 2021 Highlights

¹⁷⁷Lu-PSMA-617, Novel Targeted Therapy, Extends Survival in Men with Metastatic Prostate Cancer

Prostate Cancer ASCO 2021

¹⁷⁷Lu-PSMA-617, Novel Targeted Therapy, Extends Survival in Men with Metastatic Prostate Cancer

By Phoebe Starr

ASCO 2021 Highlights

Increasing PSA Screening in Black Men Will Improve the Diagnosis of Prostate Cancer and Reduce Deaths

Prostate Cancer ASCO 2021

Increasing PSA Screening in Black Men Will Improve the Diagnosis of Prostate Cancer and Reduce Deaths

ASCO 2021 Highlights

Challenges and Progress in the Treatment of Patients with High-Risk, Relapsed Multiple Myeloma

Multiple Myeloma ASCO 2021

Challenges and Progress in the Treatment of Patients with High-Risk, Relapsed Multiple Myeloma

By Meg Barbor, MPH

ASCO 2021 Highlights

$Patient-Reported Outcomes and Vision-Related Symptoms Can Guide the Dosing of Blenrep in Patients with Relapsed or Refractory Multiple Myeloma$

Multiple Myeloma ASCO 2021

Patient-Reported Outcomes and Vision-Related Symptoms Can Guide the Dosing of Blenrep in Patients with Relapsed or Refractory Multiple Myeloma

ASCO 2021 Highlights

New Approaches to Systemic Therapy for Patients with Stage III Melanoma

Melanoma ASCO 2021

New Approaches to Systemic Therapy for Patients with Stage III Melanoma

ASCO 2021 Highlights

1
2

Page 1 of 2
Results 1 - 10 of 20

Subscribe to CONQUER^™: the patient voice^™ magazine

Receive timely cancer news & updates, patient stories, and more.

Country

Gender

Race or Ethnicity

Hispanic, Latino, or Spanish origin

Profession or Role

Primary Interest

Print Edition

Need multiple copies? Click here

E-Newsletters & Communications

I have reviewed and consent to the terms of CONQUER's Privacy Policy, and CONQUER has my permission to retain my information in its database, and to forward pertinent communications to me.